Sandra Knowles
ARTICLES BY THIS AUTHOR
- 9/26/2024
Pseudoephedrine: risk of PRES/RCVS
The European Pharmacovigilance Risk Assessment Committee reviewed reported cases and post-marketing safety data to evaluate the risks of PRES and RCVS with pseudoephedrine-containing medicines. - 9/23/2024
Do PPIs increase risk for migraine?
Proton pump inhibitors are commonly used medications for the treatment and prevention of gastric acid-related upper gastrointestinal disease. - 6/11/2024
Safety of combining PDE5 inhibitors and nitrates
Some studies have demonstrated lower mortality with phosphodiesterase-5 inhibitor treatment for erectile dysfunction in men with stable coronary artery disease, compared with no treatment. - 6/9/2024
GLP-1 agonists and suicidality
Cases of suicidality have been reported among patients using GLP-1 receptor agonists for diabetes and/or obesity. - 10/17/2023
Hormone replacement therapy and risk of dementia
Some early studies suggested that HRT may have a protective effect on the development of Alzheimer’s disease. In contrast, other research found HRT was associated with a two-fold increased risk of dementia in women aged 65 years or older. - 10/17/2023
Benzodiazepine-related toxicity: Ontario study
In Canada, the prevalence of benzodiazepine use is estimated between 5% and 10%. - 7/23/2023
Metabolic adverse effects of antipsychotics
A recent network meta-analysis investigated the mid- to long-term metabolic effects of antipsychotics in randomized controlled trials of 13 weeks’ duration or longer in patients with schizophrenia. - 7/17/2023
Measures to reduce acetaminophen hepatotoxicity
The FDA mandate to limit the dosage of acetaminophen to 325 mg in tablets that combine acetaminophen and opioid medications significantly reduced cases of hospitalizations and serious liver injury. - 4/10/2023
Evaluating patients for drug-induced liver injury
Drug-induced liver injury can range from asymptomatic liver enzyme elevation, the most common presentation, to acute liver failure. - 4/10/2023
Hormone therapy safety in breast cancer survivors
Use of systemic and vaginal estrogens can help to mitigate unwanted effects of adjuvant endocrine therapy; however, concern has been raised regarding a possible increased risk of breast cancer recurrence.
